IKS Health reported strong growth in Q3, driven by continuous margin expansion. Revenue increased by 24% YoY in INR and 19% YoY in USD. The company’s focus on deep client relationships and a differentiated growth market strategy has yielded positive results, with EBITDA rising by 40% and PAT by 41%. This performance reinforces IKS Health’s market position.
Financial Performance Highlights
IKS Health has demonstrated significant financial growth in Q3. Key highlights include:
- Revenue: Increased to INR 8,150 million.
- EBITDA: Achieved 35% with YoY growth of 40%.
- PAT Margin: Reached 22% with YoY growth of 41%.
The company’s globally diversified workforce, comprising 13,350 employees, contributes to its operational strength. The clinical/tech-focused employee count is 2,072/542, with women comprising 45% of the workforce.
Key Business Strategies
IKS Health focuses on several strategic pillars to drive growth:
- AI-native, Agentic Platform Manifest
- AQuity Acquisition Integration & Optimization
- Establishing Leadership across features
- Differentiated Growth Market Strategy
- Evolution Towards an Outcome-Oriented Company
Awards and Recognition
IKS Health has received the following awards:
- 2026 Best in KLAS Award for Virtual Scribing Services.
- ET Edge Impactful CEO Award for Sachin K. Gupta, Founder & Global CEO.
Cash Flow and Debt
The company showcased continued strong cash generation:
- Net debt decreased to INR 3,220 million as of December 31, 2025.
9M FY26 Performance
The company has seen strong cash generation and EPS Growth:
- EPS increased by 51.5% YoY
Decade of Consistent Growth
IKS Health has shown substantial growth over the past decade:
- Revenue CAGR: 27.9%
- PAT CAGR: 32.3%
Source: BSE
